Join Now
Sign In
Cliff Hudis, MD
CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified) )| Communities: Breast Cancer | Answers: 9 |
| Member Since: Dec. 2011 |
Ask CliffHudisMD a question:
0
Cc:
Twitter
Facebook
Professional Statement
I am a medical oncologist with research interests in all areas of care related to breast cancer. My clinical practice is devoted solely to the treatment of patients with breast cancer; and my research is focused on prevention of the disease, prevention of recurrence after surgery, and treatment of recurrences.
Working with a broad team of experts at Memorial Sloan-Kettering where I am Chief of the Breast Cancer Medicine Service. Throughout the world, I am involved in clinical and translational studies that aim to develop better hormone therapies, improved chemotherapy drugs, more-effective and less-toxic methods of drug delivery, and newer highly specific agents. This work is conducted both at Memorial Sloan-Kettering, through the Breast Cancer Disease Management Team and the Breast Cancer Medicine Service, and also through my role as the Breast Committee Co-Chair of the Alliance (formerly the Cancer and Leukemia Group B - a national clinical research group sponsored by the National Cancer Institute). In addition, I am a member of the Board of Directors of American Society of Clinical Oncology (ASCO) as well as an Associate Editor of the JCO and the Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation.
Working with a broad team of experts at Memorial Sloan-Kettering where I am Chief of the Breast Cancer Medicine Service. Throughout the world, I am involved in clinical and translational studies that aim to develop better hormone therapies, improved chemotherapy drugs, more-effective and less-toxic methods of drug delivery, and newer highly specific agents. This work is conducted both at Memorial Sloan-Kettering, through the Breast Cancer Disease Management Team and the Breast Cancer Medicine Service, and also through my role as the Breast Committee Co-Chair of the Alliance (formerly the Cancer and Leukemia Group B - a national clinical research group sponsored by the National Cancer Institute). In addition, I am a member of the Board of Directors of American Society of Clinical Oncology (ASCO) as well as an Associate Editor of the JCO and the Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation.
Professional Info
Credential: MD
Primary specialty: Oncology - Hematology/Oncology
Medical school: The Medical College of Pennsylvania
Residency: Hospital of the Medical College of Pennsylvania
Fellowship: Memorial Sloan-Kettering Cancer Center
Areas of expertise: Breast Cancer
Research interests:
Prevention of the breast cancer
Prevention of recurrence after surgery
Treatment of breast cancer recurrences
Hospital affiliation: Memorial Sloan-Kettering Cancer Center
Practice phone number: 646-497-9064
Webpage:
http://www.mskcc.org/
CliffHudisMD Activities
The options for such patients have never been greater. They include continuing trastuzumab (Herceptin™) as the chemotherapy is switched, the substitution or addition of lapatinib for or with trastuzumab, and enrollment on clinical trials testing a large and growing number of HER2 directed novel therapies.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Breast Cancer Treatments, Breast Cancer Recurrence, Her2/neu, Breast Cancer, Recurrence, Trastuzumab (Herceptin), Cancer
1
Answer |
1 year ago
This is the beginning of a story. The gene set performed as a prognostic test well here. This needs to be confirmed but even more important is the need to demonstrate that it predicts, or does not predict, the benefit of radiation therapy for DCIS.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Stage 0 (DCIS) Breast Cancer, Oncotype DX, Breast Cancer Treatments, Breast Cancer
1
Answer |
1 year ago
We study many potential treatments. If the evidence rises to the level needed to confirm utility, we incorporate the results. I take great pains to point out that we do not have different standards of evidence for so-called “alternative” therapies. Furthermore, just because we study something does not mean that it is useful. In fact, and unfortunately, most drugs and substances that are studied under any circumstances do not turn out to be useful.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Mushrooms, Integrative Treatments, Integrative Medicine, Alternative Treatments, Alternative Medicine, Botanicals, Cancer Treatments, Cancer
1
Answer |
1 year ago
The drug is everolimus, an mTOR inhibitor, added to an aromatase inhibitor (exemestane, known as Aromacin). The months that it “seems” to buy are time until the cancer worsens. This is an important issue because it can be confused with survival (i.e., how long a patient lives) but it is actually not (yet) known to prolong this. It also has some real, but manageable toxicities. It represents confirmation that inhibition of mTOR can be clinically effective but the relative value of this approach and its optimal implementation remains to be more fully determined.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Progesterone Receptor Positive (PR+), Breast Cancer Treatments, Everolimus, Breast Cancer, Mtor Inhibitor, Estrogen Receptor Positive (ER+)
1
Answer |
1 year ago
I think this is an artificial distinction. We either have evidence, or we do not. Or we have weak versus strong evidence. I evaluate all interventions using the same standards. Nutrition is clearly an important component of health and we know that in general a low-fat, calorie-restricted diet, is healthier in myriad ways than another. However, the evidence that any particular component of the diet, or supplement, can prevent or treat illness is weak to non-existent. This limits our ability to endorse any specific recommendation.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Breast Cancer, Integrative Medicine, Alternative Treatments, Alternative Medicine, Vitamin D, Nutrition, Cancer
1
Answer |
1 year ago
Weight control and exercise are the two related factors that are truly under our control and that might have a bearing on the outcome of treatment for early stage breast cancer.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Health, Reduce Breast Cancer Risk, Lifestyle Modifications, Reduce Cancer Risk, Lifestyle
2
Answers |
1 year ago
As a first approximation this is not really a concern. When chemotherapy (in general) is needed, the subtype of breast cancer does not have a reliable association with the benefits of individual drugs and regimens.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Breast Cancer Treatments, Breast Cancer, Breast Cancer Type, Chemotherapy
1
Answer |
1 year ago
Olaparib was developed to specifically target PARP, which becomes more critical in cancers that develop as a consequence of an inherited mutation in the DNA-repair genes. Its activity is largely confined to those breast and ovary cancers that have defective BRCA genes on the basis of inheritance. It could similarly be active in other cancers, such as Pancreatic, that are associated with these genetic defects but more data is needed.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Olaparib, Breast Cancer Treatments, PARP, BRCA Mutations, Chemotherapy
1
Answer |
1 year ago
There is a small numerical advantage, on average, associated with the use of aromatase inhibitors over tamoxifen. However, that does not mean that every single patient must use the AIs. If the AIs are intolerable it is reasonable to use tamoxifen instead.
New answer by CliffHudisMD (Physician - Oncology - Hematology/Oncology (Verified)) in topic(s) Breast Cancer Treatments, Breast Cancer, Aromatase Inhibitors, Joint Pain, Side Effects, Nolvadex (Tamoxifen)
1
Answer |
1 year ago
CliffHudisMD's Profile
Newsletters
Sign up for email updates of the latest news, best answers, and featured experts.
Benefits
Custom health, wellness, & medical offers including clinical trials, market research opportunities, & new programs.
Share TalkAboutHealth
To share TalkAboutHealth with friends, type their email addresses here (separated by commas):
From:
Add a personal note here:
Please join TalkAboutHealth and you will be able to ask questions.
Your question to CliffHudisMD:
2) Background Info (optional): What context or background information is relevant to this request?
Notes:
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
Newsletters
